Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of AB-101 hydrogel for mild to moderate atopic dermatitis
ACTRN12622000395730Phase 2Completed
- Sponsor
- Alphyn Biologics
- Start
- May 2022
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial in atopic dermatitis (AD) comparing AB-101 hydrogel with Hydrogel vehicle placebo (2 arms). Primary endpoints: Safety and tolerability and At least 1-point improvement in Investigator Global Assessment. Started May 2022; status: completed.
02
Drugs
zabalafin
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ACTRN12622000395730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000395730.